



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Programme Director of the NIHR Efficacy and Mechanism Evaluation programme.

Ellen Gorman, Bronwen Connolly, Keith Couper,
Gavin D Perkins, *Daniel F McAuley
d.f.mcauley@qub.ac.uk

Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK (EG, BC, DFM); Critical Care Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (KC, GDP); Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK (KC, GDP); Regional Intensive Care Unit, Belfast Health and Social Care Trust, Belfast, UK (DFM)

- 1 Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020; **369**: m1985.
- 2 Azoulay E, de Waele J, Ferrer R, et al. International variation in the management of severe COVID-19 patients. *Crit Care* 2020; **24**: 486.
- 3 Grieco DL, Menga LS, Cesarano M, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. *JAMA* 2021; published online March 25. <https://doi.org/10.1001/jama.2021.4682>.
- 4 Ashish A, Unsworth A, Martindale J, et al. CPAP management of COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation. *BMJ Open Respir Res* 2020; **7**: e000692.
- 5 Demoule A, Vieillard Baron A, Darmon M, et al. High-flow nasal cannula in critically ill patients with severe COVID-19. *Am J Respir Crit Care Med* 2020; **202**: 1039–42.
- 6 Arina P, Baso B, Moro V, et al. Discriminating between CPAP success and failure in COVID-19 patients with severe respiratory failure. *Intensive Care Med* 2021; **47**: 237–39.
- 7 Ferreyro BL, Angriman F, Munshi L, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis. *JAMA* 2020; **324**: 57–67.
- 8 Esquinas AM, Egbert Pravinkumar S, Scala R, et al. Noninvasive mechanical ventilation in high-risk pulmonary infections: a clinical review. *Eur Respir Rev* 2014; **23**: 427–38.
- 9 Tobin M. Basing respiratory management of COVID-19 on physiological principles. *Am J Respir Crit Care Med* 2020; **201**: 1319–20.
- 10 Elhakit TS, Abdul HS, Pelaez Romero C, Rodriguez-Fuentes Y. Spontaneous pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19 pneumonia: a rare case and literature review. *BMJ Case Rep* 2020; **13**: e239489.
- 11 Perkins GD, Couper K, Connolly B, et al. RECOVERY-Respiratory Support: respiratory strategies for patients with suspected or proven COVID-19 respiratory failure; continuous positive airway pressure, high-flow nasal oxygen, and standard care: a structured summary of a study protocol for a randomised controlled trial. *Trials* 2020; **21**: 687.
- 12 Coppadoro A, Benini A, Fruscio R, et al. Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19



Challenges and opportunities to end tuberculosis in the COVID-19 era

Published Online
March 24, 2021
[https://doi.org/10.1016/S2213-2600\(21\)00161-2](https://doi.org/10.1016/S2213-2600(21)00161-2)

On World Tuberculosis Day, 2020, we warned of the impending impact of COVID-19 on the tuberculosis pandemic. We also made a plea that the world must not forget tuberculosis while it focused on COVID-19.¹

1 year later, on World Tuberculosis Day, 2021, we reflect on the compelling evidence of the challenges that COVID-19 has created for tuberculosis control and look forward to opportunities for integrated strategies to address the COVID-19 and tuberculosis pandemics.

We are not on course to eliminate tuberculosis. The Stop TB Partnership estimates that the past 12 months have pushed back global tuberculosis progress by 12 years.² Achieving the WHO's End TB Strategy goals will require an estimated US\$15 billion additional funding annually. Less than half of the funding commitments made at the 2018 UN High Level Meeting on tuberculosis have been delivered. Cuts to the UK overseas Official Development Assistance will further contribute to this shortfall.

COVID-19 has challenged health systems and restricted essential health service delivery.³ Health system infrastructure, from diagnostic tools to the workforce, has pivoted towards COVID-19 and away from competing

illnesses, including tuberculosis.⁴ Health-care access has been constrained due to transport disruptions, restricted movement, reduced opening hours, depleted staffing levels, fear, and stigma.⁵

In nine countries with a high tuberculosis burden, which contribute 60% of the world's tuberculosis cases, tuberculosis diagnosis and treatment decreased by 23%, equating to 1 million missed cases. Similar to the 2014–15 Ebola virus disease outbreaks, restricted access to health care has led to an increase in late, disseminated presentations of tuberculosis, associated with adverse treatment outcomes and death.² Indeed, the COVID-19 pandemic is predicted to increase tuberculosis deaths globally by 20% over the next 5 years.⁶

These challenges to tuberculosis diagnosis, notification, care, and cure, are especially concerning in the context of global antimicrobial resistance. Despite multidrug-resistant (MDR) tuberculosis being estimated to contribute up to one third of deaths from antimicrobial resistance globally, the minority of people with MDR tuberculosis have access to all-oral treatment regimens. Long, toxic regimens involving intravenous or intramuscular injections remain the mainstay in many

low-income and middle-income countries (LMICs) with high tuberculosis burdens. These regimens are costly for patients and the health system with low rates of adherence and treatment success. These conditions, coupled with COVID-19-related difficulties for people with tuberculosis to engage with care, are likely to foment drug resistance and threaten tuberculosis being treatable with a return to the preantibiotic era.

To avoid further unacceptable morbidity and mortality, effective, person-centred strategies are urgently required to mitigate the impact of COVID-19 on tuberculosis. There are many opportunities to learn from and integrate COVID-19 and tuberculosis strategies to deliver health interventions with broader benefits on prevention, case-detection, and care of COVID-19, tuberculosis, and other illnesses.

COVID-19 has demonstrated what the scientific community can deliver with political will and funding. Large-scale, adaptive, randomised trials have provided rapid evidence on effective new COVID-19 treatments. Conversely, apart from bedaquiline and delamanid, novel drug development for tuberculosis has been stagnant for decades. With regards to prevention, multiple COVID-19 vaccines, which appear effective in preventing SARS-CoV-2 infection and COVID-19 disease, are being rolled out within a year of the pandemic onset. In contrast, the BCG vaccine is a century old and ineffective in adults, and the tuberculosis vaccine pipeline is strikingly sparse. However, the infrastructure, investment, supply chain, and uptake of COVID-19 vaccines represent an opportunity for future tuberculosis vaccination programmes, including the promising M72/AS01 E tuberculosis vaccine.⁷ In addition, mRNA technology used to develop COVID vaccines has great potential to be reconfigured to other infections, including tuberculosis.

In many settings, GeneXpert machines have been largely repurposed to test for SARS-CoV-2 during the pandemic. However, as the Stop TB Partnership rightly notes: "Tuberculosis testing must continue". Increased funding, logistics, training, staffing, transport systems, and use of GeneXpert could support enhanced tuberculosis diagnosis, early case detection, and resistance testing. More broadly, there might be opportunities to overcome silos in diagnostic facilities and develop enhanced multiplex platforms to simultaneously test for several priority diseases.

Bilateral tuberculosis and COVID-19 case-finding and testing among people with respiratory symptoms or predisposing comorbidities, such as HIV and diabetes, are likely to be cost-effective and prepare health systems for a rapid response to future respiratory threats.

Community-based and community-led responses that take diagnosis, care, and support to the doors of those affected have much potential. For example, people with respiratory symptoms and illness should be able to receive community-based contact tracing, directly observed therapy, and isolation and quarantine support from trusted friends, family, or neighbours.⁴ Such strategies could improve distribution and use of appropriate personal protective equipment, reduce nosocomial transmission of communicable respiratory diseases, and improve the value-for-money of trained health-care worker time. They will also be vital for longer term management of people with post-COVID or post-tuberculosis lung disease and complications,⁸ conditions which require more coordinated research and intervention. In some countries, careful targeted use of artificial intelligence software and digital radiography has the potential to be used to support enhanced contact tracing and outreach strategies for communicable respiratory illnesses.⁴

Accurate information and education is essential. Governments and health systems should aim to integrate evidence-based public health messaging about tuberculosis, COVID-19, and other respiratory conditions. Moreover, achieving successful public health campaigns will be impossible without meaningful engagement with communities, civil-society representatives, and advocacy groups. This engagement is imperative to dispel myths,




Figure: Proportion of people with tuberculosis and their households facing catastrophic costs in 17 national surveys completed since 2015
 Percentages refer to the pooled average value across all surveys, with the range representing the minimum and maximum values in the 17 countries. Reproduced with permissions from WHO's Global Tuberculosis Report 2020.¹²

reduce stigma and fear, change health behaviour, and improve access to services.

COVID-19, tuberculosis, and respiratory illnesses typify health inequality, are strongly associated with poverty, and share biosocial determinants, including undernutrition or malnutrition, ethnicity, and belonging to marginalised, underserved groups.^{9,10} Globally, the COVID-19 pandemic has worsened impoverishment and nutrition for millions of vulnerable households, and lockdown and stay-at-home measures pose a risk of increased tuberculosis transmission, especially with concomitant overcrowding.

For those diagnosed with tuberculosis, holistic, person-centred care and support has been difficult to maintain during the COVID-19 pandemic. While potentially beneficial, virtual consultations and adherence support, including video observed therapy, is not available routinely in many LMICs. Moreover, there have been colossal challenges to delivering food, economic, and psychosocial support to tuberculosis-affected households during COVID-19 times,⁴ which might increase their likelihood of incurring catastrophic tuberculosis-related costs (figure).¹¹ This serves to re-emphasise the crucial importance of social protection and universal health coverage to provide income security, enable health-care access, and reduce out-of-pocket health-care expenditure.

On World Tuberculosis Day, 2021, our year-old plea to not forget tuberculosis is now more important and relevant than ever: one person dies of tuberculosis every 20 s. The clock is ticking.

TW is supported by grants from the Wellcome Trust (209075/Z/17/Z and Joint Global Health Trials, MR/V004832/1), the Medical Research Council (MRC), Department for International Development, the Academy of Medical Sciences, and the Swedish Health Research Council. LEC is supported by grants from the European and Developing Countries Clinical Trial Partnership (EDCTP, DRIA2014-309), the MRC, the TB REACH Initiative of the Stop TB Partnership (STBP/TBREACH//GSA/W5-07), the Wellcome Trust (contract pending), and the Health Protection Research Unit for Emerging and Zoonotic Infections. PM is funded by the Wellcome Trust (206575/Z/17/Z). KAM works on projects funded with UK aid from the UK Government. SBS is supported by the National Institute

for Health Research Global Health Research Unit on Lung Health and TB in Africa at the Liverpool School of Tropical Medicine (16/136/35) and the Foreign, Commonwealth and Development Office Research Programme Consortium Leaving no-one behind, transforming gendered pathways to health for TB (LIGHT PO8614). All authors declare no competing interests.

*Tom Wingfield, Fatima Karmadwala, Peter MacPherson, Kerry A Millington, Naomi F Walker, Luis E Cuevas, S Bertel Squire

tom.wingfield@lstmed.ac.uk

Departments of Clinical Sciences and International Public Health, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK (TW, LEC, PM, KAM, SBS, NFW, FK); Social Medicine, Infectious diseases, and Migration Group, Department of Global Public Health Sciences, Karolinska Institutet, Stockholm, Sweden (TW); Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK (TW, SBS, NFW); Zankli Research Centre, Bingham University, Nasarawa State, Nigeria (LEC); Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi (PM); and Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK (PM)

- 1 Wingfield T, Cuevas LE, Macpherson P, Millington KA, Squire SB. Tackling two pandemics: a plea on World Tuberculosis Day. *Lancet Respir Med* 2020; **8**: 536–38.
- 2 The Stop TB Partnership. 12 months of COVID-19 eliminated 12 years of progress in the global fight against tuberculosis. March 18, 2021. http://www.stoptb.org/news/stories/2021/ns21_011.html (accessed March 22, 2021).
- 3 Alagna R, Besozzi G, Codecasa LR, et al. Celebrating world tuberculosis day at the time of COVID-19. *Eur Respir J* 2020; **55**: 20000650.
- 4 Malik AA, Safdar N, Chandir S, et al. Tuberculosis control and care in the era of COVID-19. *Health Policy Plan* 2020; **35**: 1130–32.
- 5 Khan MD, Rego S, Rajal JB, et al. Mitigating the impact of COVID-19 on tuberculosis and HIV services: a cross-sectional survey of 669 health professionals in 64 low and middle-income countries. *PLoS One* 2021; published online Feb 2. DOI:10.1371/journal.pone.0244936.
- 6 Hogan, AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. *Lancet Glob Health* 2020; **8**: e1132–41.
- 7 Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01 E vaccine to prevent tuberculosis. *N Engl J Med* 2019; **381**: 2429–39.
- 8 Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. *Lancet* 2021; published online Feb 22. [https://doi.org/10.1016/S0140-6736\(21\)00458-X](https://doi.org/10.1016/S0140-6736(21)00458-X).
- 9 Pedrazzoli D, Wingfield T. Biosocial strategies to address the socioeconomic determinants and consequences of the TB and COVID-19 pandemics. *Am J Trop Med Hyg* 2021; **104**: 407–09.
- 10 Wingfield T, Tovar MA, Datta S, Saunders MJ, Evans CA. Addressing social determinants to end tuberculosis. *Lancet* 2018; **391**: 1129–32.
- 11 Tran PB, Hensing G, Wingfield T, et al. Income security during public health emergencies: the COVID-19 poverty trap in Vietnam. *BMJ Glob Health* 2020; **5**: e002504.
- 12 WHO. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.



Evidence-based European guidelines for the diagnosis of asthma in children aged 5–16 years

Published Online
April 21, 2021
[https://doi.org/10.1016/S2213-2600\(21\)00183-1](https://doi.org/10.1016/S2213-2600(21)00183-1)

Asthma is the most common non-communicable disease in children, but there is no single test available to confirm the diagnosis. In most cases, the diagnosis

in children is made in non-specialist settings on the basis of clinical history and physical examination alone.¹ Lingering respiratory symptoms, such as prolonged